1. Abbasi F, Chu JW, McLaughlin T et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004; 53 (2): 159–64.
2. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti-diabetic agents. Diab Vasc Dis Res 2006; 3 (3): 147–58.
3. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574–9.
4. Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 2012; 8 (5): 907–17.
5. Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events, a metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12,4 years. Diabetes Care 1999; 22: 233–40.
6. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifesyill intervention or metformin. N Engl J Med 2002; с. 346, 393–403.
7. Dunstan DW, Zimmet PZ, Welborn TA et al. The rising prevalence of diabetes mellitus and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829–34.
8. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309–14.
9. Gagnon J, Sheppard E, Anin YI. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diab Obes and Metab 2013;15 (3): 276–9.
10. Grand PJ. Beneficial effects of metformin on hemostasis and vascular function in man. Diabetes Metаb 2003; 29: 6S45–6S52.
11. Haffner SM, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229–34.
12. He L, Sabet A, Djedjos S et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 15; 137 (4): 635–46.
13. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome; http://www.idf.org/webdata/docs/
IDF_Metasyndrome_definition.pdf Accessed October 4, 2005.
14. Isoda K, Young JL, Zirlik A et al. Metformin inhibits proinflammatory responses and nuclear Factor-kappa B in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26 (3): 611–7.
15. Kolluru GK, Bir SC, Kevil CG. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; doi: 10.1155/2012/918267.
16. Malesker MA. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy 2008; 28 (2): 193–206.
17. Mazzone T, Chait A, Plutsky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008; 371: 1800–9.
18. Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag 2009; 5: 859–71.
19. Bailey CJ, Campbell IW, Chan JCN et al. Metformin. The gold standard. A scientific handbook (Text). England: John Wiley & Sons, Ltd, 2007.
20. Miranda PJ, De Fronzo RA, Califf RM, Guyton JR. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005; 149 (1): 33–45.
21. Ouslimani N, Mahrouf M, Peynet J et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin-like oxidized receptor 1. Metabolism 2007; 56 (3): 308–13.
22. Park JH, Kwon HM, Roh JK. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis. Eur J Neurol 2007; 14 (4): 379–86.
23. Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121: 149–57.
24. Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Vasc Dis Res 2008; 5: 157–67.
25. Standards of Medical Care in Diabetes 2011. Diabetes Care 2011; 34 (Suppl. 1): 11–61.
26. Standards of Medical Care in Diabetes 2012. Diabetes Care 2012; 35 (Suppl. 1): 11–63.
27. Viollet B, Guigas B, Garcia NS. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122 (6): 253–70.
28. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–8.
29. Uygun A et al. Metformin in the treatment of patients with non-alcoholic steatogepatitis. Phormacol Ther 2004; 19: 537–44.
30. Viner RM, Segal TY, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005; 90: 10–4.
31. Zimmet PZ, Alberti KG. Introduction: Globalization and the non-communicable disease epidemic. Obesity (Silver Spring) 2006; 14: 1–3.

Е.В.Бирюкова

Кафедра эндокринологии и диабетологии ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ